Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magdalena A Taracila

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|August 24, 2011
Carbapenems: past, present, and futureKrisztina M Papp-Wallace, Andrea Endimiani, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2015
Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactamKrisztina M Papp-Wallace, Marisa L Winkler, Magdalena A Taracila, et al.
Chemmedchem|May 28, 2020
α-Triazolylboronic Acids: A Promising Scaffold for Effective Inhibitors of KPCsMaria Luisa Introvigne, Magdalena A Taracila, Fabio Prati, et al.
Infectious Disease Clinics of North America|October 4, 2020
Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress"Krisztina M Papp-Wallace, Andrew R Mack, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2015
Avibactam and inhibitor-resistant SHV β-lactamasesMarisa L Winkler, Krisztina M Papp-Wallace, Magdalena A Taracila, et al.
Journal of Medicinal Chemistry|June 24, 2015
Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase InhibitorsEmilia Caselli, Chiara Romagnoli, Roza Vahabi, et al.
Antimicrobial Agents and Chemotherapy|August 22, 2012
Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistanceMei Li, Benjamin C Conklin, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2013
N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactamMarion J Skalweit, Mei Li, Benjamin C Conklin, et al.
Protein Science : a Publication of the Protein Society|December 21, 2016
Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamaseJosephine P Werner, Joshua M Mitchell, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276Krisztina M Papp-Wallace, Magdalena A Taracila, Kerri M Smith, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|August 24, 2011
Carbapenems: past, present, and futureKrisztina M Papp-Wallace, Andrea Endimiani, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2015
Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactamKrisztina M Papp-Wallace, Marisa L Winkler, Magdalena A Taracila, et al.
Chemmedchem|May 28, 2020
α-Triazolylboronic Acids: A Promising Scaffold for Effective Inhibitors of KPCsMaria Luisa Introvigne, Magdalena A Taracila, Fabio Prati, et al.
Infectious Disease Clinics of North America|October 4, 2020
Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress"Krisztina M Papp-Wallace, Andrew R Mack, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2015
Avibactam and inhibitor-resistant SHV β-lactamasesMarisa L Winkler, Krisztina M Papp-Wallace, Magdalena A Taracila, et al.
Journal of Medicinal Chemistry|June 24, 2015
Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase InhibitorsEmilia Caselli, Chiara Romagnoli, Roza Vahabi, et al.
Antimicrobial Agents and Chemotherapy|August 22, 2012
Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistanceMei Li, Benjamin C Conklin, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2013
N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactamMarion J Skalweit, Mei Li, Benjamin C Conklin, et al.
Protein Science : a Publication of the Protein Society|December 21, 2016
Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamaseJosephine P Werner, Joshua M Mitchell, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276Krisztina M Papp-Wallace, Magdalena A Taracila, Kerri M Smith, et al.
Pageof 7